About Blacksmith Medicines
Blacksmith Medicines develops a platform for medicines for immuno-oncology and inflammatory diseases. The platform uses metalloenzyme-targeted medicines that combine a focused library of metal-binding pharmacophores with proprietary computational modeling approaches to rapidly and rationally design small molecule inhibitors that interact with key metal ions in the enzyme's active site. The company was founded in 2017 and is based in San Diego, California. In January 2023, Blacksmith Medicines merged with Forge Therapeutics.
Blacksmith Medicines Patents
Blacksmith Medicines has filed 2 patents.
Inflammations, Bacterial diseases, Infectious diseases, Antibiotics, Syndromes
Inflammations, Bacterial diseases, Infectious diseases, Antibiotics, Syndromes
Latest Blacksmith Medicines News
Jan 17, 2023
Katherine Lewin News Reporter Blacksmith Medicines and Forge Therapeutics announced Monday that the companies are merging only a year after Blacksmith launched as a spinout of Forge, but there is little information provided on the unification. The focus will be on infection and oncology research to develop drugs to target metalloenzymes, or enzyme proteins that contain a metal ion like magnesium, zinc, iron, manganese, calcium, cobalt or copper and perform a wide range of functions in the body from mitochondrial function to nitric oxide production. Metalloenzymes account for over 30% of all known enzymes across all species. “Our target strategy is to focus on metalloenzymes of significant unmet need and high pharma interest, targets with validated biology that have been challenging to drug due to chemistry limitations that we can solve with our platform,” Blacksmith co-founder and CEO Zachary Zimmerman said in a statement. Blacksmith launched i n January 2021 with a potential $300 million collaboration agreement with Eli Lilly to develop small molecule inhibitors for metalloenzymes, as well as a goal to expand the reach of Forge’s tech platform into areas outside of anti-infectives. Investors included Evotec, MagnaSci Ventures, MP Healthcare Partners and Alexandria Venture Investments. What does Blacksmith bring back to Forge’s table? Collaborations that could potentially earn more than $800 million in milestone payments and royalties and federal awards of up to $25.3 million for its infectious disease programs, as well as extensive libraries of metal-binding pharmacophores and a comprehensive picture of the metalloenzyme genome, according to the company. Forge first announced the BLACKSMITH platform in 2017, with an initial focus on infectious diseases and metalloenzymes. The parent company has had its own successes in the past few years. In 2019, Forge partnered up with Basilea to discover, develop, and commercialize antibiotics as part of its focus on drug resistance. Forge scored a $190.5 million research deal with Roche in 2020 that gave the Swiss drugmaker the option to license an experimental antibiotic being developed for use in serious lung infections. AUTHOR Amber Tong Senior Editor An IPO was off the table, but the immunotherapy experts at Elicio Therapeutics found a way to the public markets after all. Elicio is merging with Angion Biomedica, a Uniondale, NY-based biotech that began searching for strategic alternatives last July after Phase II setbacks forced it to shutter all R&D work. In classic reverse merger fashion, the combined company will operate under the Elicio name and focus on Elicio’s lymph node-targeting approach to treating cancer and other diseases — with the Elicio executive team, led by CEO Robert Connelly, running the show. The stock ticker will change, too: from $ANGN to $ELTX . Keep reading Endpoints with a free subscription Unlock this story instantly and join 156,100+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Amber Tong Senior Editor Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here . Hello — we know it’s not Saturday but Monday, but since Endpoints News is taking a break for MLK Day, we thought we’d change up the time this week. Whether you’re recovering from the JP Morgan conference like me or watched from afar, this edition of the Endpoints Weekly has got you covered on everything you need to know from last week. I was thrilled to meet some of you in San Francisco and learned so much from conversations, formal or informal. It’s been more than three years since I’ve stepped foot in the US (or left Asia! ), so the trip was extra special. Keep reading Endpoints with a free subscription Unlock this story instantly and join 156,100+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Amber Tong Senior Editor SAN FRANCISCO — Sanofi CEO Paul Hudson sees Big Pharma being “clearly hesitant” to jump on major M&A deals amid a confluence of uncertainties, from the newly passed Inflation Reduction Act to the looming patent cliff for many of the major medicines currently on the market. Speaking to a small group of reporters on the outskirts of #JPM23 flanked by his C-suite, Hudson suggested Sanofi shares the hesitation but is not in a rush to act because of the internal pipeline that R&D chief John Reed has built up over the past four years, when the French pharma giant joined its peers in turning itself into a “science-led” company. Keep reading Endpoints with a free subscription Unlock this story instantly and join 156,100+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Beth Snyder Bulik Senior Editor Myovant and Pfizer are pointing up the fact that prostate cancer treatment Orgovyx is a pill in the first direct-to-consumer campaign for the brand. The advertising pulls the middle syllable from the brand name, encouraging people to “GO with the facts” and talk to a doctor about the oral androgen deprivation therapy (ADT). Real patients and caregivers are featured on the brand website, which also includes a link to an Orgovyx resource called “The MANual.” That platform, launched last year, is meant to help patients when starting on the drug and includes a tracking app, educational material and prostate cancer support community connections. Keep reading Endpoints with a free subscription Unlock this story instantly and join 156,100+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Beth Snyder Bulik Senior Editor The pharma industry knocked off the tech industry to take the No. 1-trusted industry spot in Ipsos’ just-released annual survey. More than one third (34%) of adults surveyed across 21 countries rated pharma companies as trustworthy, edging out the tech sector with a 33% average score. While the rankings are relative, it’s still good news for pharma, which increased from 31% last year. Tech stayed even year-over-year, but it’s dropped from a high of 38% in 2018, the first year of the Ipsos Global Trustworthiness Monitor report. Other sectors that also increased for 2022 were government at 22%, up from 20% last year, and social media, also at 22% and up from 16% last year. Keep reading Endpoints with a free subscription Unlock this story instantly and join 156,100+ biopharma pros reading Endpoints daily — and it's free. SIGN UP LOG IN
Blacksmith Medicines Frequently Asked Questions (FAQ)
When was Blacksmith Medicines founded?
Blacksmith Medicines was founded in 2017.
Where is Blacksmith Medicines's headquarters?
Blacksmith Medicines's headquarters is located at 10578 Science Center Drive, San Diego.
What is Blacksmith Medicines's latest funding round?
Blacksmith Medicines's latest funding round is Merger.
Who are the investors of Blacksmith Medicines?
Investors of Blacksmith Medicines include Forge Therapeutics, MP Healthcare Venture Management, Eli Lilly and Company, Evotec SE, Alexandria Venture Investments and 3 more.